0001479290-18-000080.txt : 20180511 0001479290-18-000080.hdr.sgml : 20180511 20180511203052 ACCESSION NUMBER: 0001479290-18-000080 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180510 FILED AS OF DATE: 20180511 DATE AS OF CHANGE: 20180511 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Russell Angus C. CENTRAL INDEX KEY: 0001534002 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 18828476 MAIL ADDRESS: STREET 1: C/O INTERMUNE, INC. STREET 2: 3280 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-742-3400 MAIL ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 4 1 wf-form4_152608499215478.xml FORM 4 X0306 4 2018-05-10 0 0001479290 Revance Therapeutics, Inc. RVNC 0001534002 Russell Angus C. C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK CA 94560 1 0 0 0 Common Stock 2018-05-10 4 A 0 3000 0 A 6000 D Stock Option (Right to buy) 29.15 2018-05-10 4 A 0 6000 0 A 2028-05-09 Common Stock 6000.0 6000 D Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 10, 2019, subject to Mr. Russell's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. The shares subject to the stock option shall vest on the one year anniversary, May 10, 2019, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. /s/ Gordon Ho, Attorney-in-Fact 2018-05-11